Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price used: about $13 per share. The latest quotes I could find were $12.83 on Oct 27 and $13.55 on Oct 29, 2026. I found no November print, so treat the price as approximate. The 52-week range is roughly $2.75 to $15.02. Per the 10-Q, shares outstanding were 326.6M at Nov 4, 2026, plus 3.08M pre-funded warrants. We are being asked to value a clinical-stage antibody company that earned about $23M of revenue in nine months and lost $139M. At roughly $13 a share it has a market capitalization near $4.3 billion. That is about $3.5 billion after netting out $764M of cash and securities. The company is not a fraud and it is not broke. The balance sheet is strong, and the August 2026 Phase 2 result for ABCL635 was good. But the stock roughly doubled into that data and now prices in a success that has not yet happened.
Recent filings analysed: 10-Q (2026-11-09), 8-K (2026-11-09), 10-Q (2026-08-05), 8-K (2026-08-05).
Stock screener · Superinvestor 13F holdings · Analyst sentiment